Result of AGM

RNS Number : 4856B

Ergomed plc

10 June 2021

 

PRESS RELEASE

Results of 2021 Annual General Meeting and Board Appointment

Guildford, UK - 10 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders at its Annual General Meeting ('AGM') held earlier today were passed by way of a poll. 

The full text of the resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com .

Further to the Company's announcement on 10 May 2021, Mark Enyedy was appointed to the Company's Board of Directors as a Non-Executive Director with effect from closing of the AGM.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]
Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit:  http://ergomedplc.com .

 

END

 

 

RAGVBLBFFQLEBBZ